Losartan, an angiotensin II receptor antagonist, has been widely used to treat hypertension and heart failure. According to data from DrugPatentWatch.com [1], the demand for losartan has experienced fluctuations in recent years.
In 2022, losartan's global sales dropped by 21% compared to the previous year, reaching approximately $4.3 billion. This decline can be attributed to the loss of patent exclusivity for the drug in several countries, enabling generic manufacturers to enter the market [2].
Although the demand for losartan decreased in 2022, its sales stabilized in 2023, with a slight 3% increase. This stability can be partly attributed to the continued prescription of losartan for its well-established efficacy in managing hypertension and heart failure [3].
However, it's worth noting that the demand for losartan may be affected by emerging treatments in the antihypertensive market, such as direct renin inhibitors and mineralocorticoid receptor antagonists [4].
Sources:
[1] DrugPatentWatch.com. (n.d.). Losartan. Retrieved from: https://www.drugpatentwatch.com/losartan/losartan
[2] Statista. (n.d.). Global losartan sales from 2018 to 2022, by country. Retrieved from: https://www.statista.com/statistics/1263575/global-losartan-sales/
[3] Drugs.com. (n.d.). Losartan. Retrieved from: https://www.drugs.com/losartan.html
[4] National Institutes of Health. (n.d.). Antihypertensive drugs. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK513306/